DREDGECAP
NASDAQ·Biological Products, (No Diagnostic Substances)

BIIBBIOGEN INC.

Last filing: 8-K·May 14, 2026EDGAR ↗
BIIB Overview
10-QApril 29, 20264/29/26· Quarter Ended March 31, 2026· Q-End 3/31/26

BIIB10-Q Filing

Track for Alerts

Financial Highlights

Structured-data extract from the filer's SEC-tagged XBRL. Every value below is sourced from a labeled XBRL concept; hover any cell to see the exact source. No AI summarization, no paraphrasing.

Income Statement

ItemMar 31, 2026Mar 31, 2025YoY
Revenue$2.48B$2.43B↑ +1.9%
Cost of Revenue$661.00M$629.30M
Operating Income (Loss)
Net Loss from Continuing Operations(derived)$319.50M$240.50M↑ +32.8%
Net Income (Loss) — Total$319.50M$240.50M↑ +32.8%

Balance Sheet

ItemMar 31, 2026Mar 31, 2025YoY
Total Assets$29.48B$28.03B
Total Liabilities$10.83B$11.05B
Stockholders' Equity$18.65B$16.98B↑ +9.9%
Accumulated Deficit$20.87B$19.50B
Cash and Cash Equivalents$3.38B$2.60B↑ +30.2%
Shares Outstanding

Cash Flow

ItemMar 31, 2026Mar 31, 2025YoY
Operating Cash Flow$645.50M$259.30M↑ +148.9%
Source filings — every value above is extracted verbatim from these SEC submissions:

BIIB Legal Proceedings Disclosed

Securities / Shareholder
Extracted from BIIB’s 10-Q filed April 29, 2026. The text below is the company’s own disclosure language; DredgeCap has not paraphrased, classified, or summarized it.
Disclosure:Legal proceedings described above may contain allegations that have not been proven. Filings often disclose claims that are later dismissed, settled, or resolved without admission of wrongdoing. DredgeCap surfaces the company’s own disclosure language for investor-risk research only. This is not legal advice or investment advice.
Current DredgeCap Risk Profile
3.2/10
MODERATE RISK
Dilution Risk
LOW2.0/10
Liquidity Risk
LOW2.0/10
Debt Toxicity
LOW2.5/10
Profitability Risk
MODERATE3.5/10
Going Concern✓ Not flagged
The risk profile above reflects the latest cached DredgeCap analysis for BIIB. For the full filing-by-filing analyst report (red flags, primary risk driver, what moves the stock), open BIIB's company page.

What is a 10-Q?

A quarterly report covering the three months just ended. Includes unaudited condensed financial statements (balance sheet, income statement, cash flow), Management Discussion and Analysis (MD&A), and disclosure of material changes since the last annual report. Required for the first three fiscal quarters; the fourth quarter is rolled into the 10-K.

More on BIIB

Dilution Analysis
Debt Structure
Going Concern
Full Financials
Form-type explainers and 8-K item descriptions are derived from SEC documentation. Financial values are extracted from SEC-tagged XBRL — see the "Source filings" list above each table for direct EDGAR links to every cited filing. This page does not constitute investment advice. Always consult the original filing on SEC EDGAR for authoritative content, and consult a licensed financial advisor for investment decisions.